Aurobindo Pharma’s Arm Receives Recognition From USFDA

Apitoria Pharma Pvt. Ltd., a subsidiary of Aurobindo Pharma Limited, has achieved a significant milestone with its Unit-2 manufacturing facility receiving a prestigious classification from the United States Food and Drug Administration (US FDA). This achievement reflects the company’s adherence to stringent quality standards and its commitment to producing high-quality Active Pharmaceutical Ingredients (APIs).

US FDA Inspection of Unit-2

The US FDA conducted a thorough inspection of Apitoria Pharma’s Unit-2, located in Gaddapotharam Village, Telangana, from September 23 to 27, 2024. As a result of this detailed review, the unit received an Establishment Inspection Report (EIR) with a classification of “Voluntary Action Indicated” (VAI). This signifies that while some minor deficiencies were noted, they do not pose any threat to product quality or safety, demonstrating the unit’s compliance with US FDA regulations.

Significance of the VAI Classification

The VAI classification is a significant acknowledgement from the US FDA. It confirms that the facility meets the required manufacturing standards and can continue its operations without facing any major regulatory hurdles. This recognition strengthens the company’s reputation globally and positions Apitoria Pharma as a trusted API manufacturer.

Aurobindo Pharma Share Performance

As of January 28, 2025, 12:47 PM, the shares of Aurobindo Pharma are trading at ₹1,151.00 per share with a surge of 2.64% from its previous day’s closing price. Over the last month, the stock has declined by 11.35%.

Conclusion

Apitoria Pharma Pvt. Ltd.’s Unit-2 achieving VAI classification is a testament to its commitment to maintaining quality and regulatory compliance. This accomplishment underscores its role as a reliable contributor to the pharmaceutical industry and its continued focus on excellence.